Home

Deck

Gujarat State Fertilizers & Chemicals · GSFC · NSE

Gujarat State Fertilizers & Chemicals is a Gujarat-government PSU at Vadodara — India's #1 caprolactam producer — that sells regulated fertilizers (urea, DAP, NPK, ammonium sulphate) and industrial chemicals, backed by an investment portfolio that equals 72% of its market cap. Figures converted from INR at historical FX rates; ratios and multiples are unchanged.

$1.86
Price
$742M
Market cap
$1.1B
Revenue (FY25)
$3.31
Book value/share
Listed on BSE since the 1970s; sank to $0.41 in March 2020, ran to $3.72 by January 2024 on the caprolactam-spread peak, now back to $1.86 at 0.56× book.
2 · The tension

$535M of trapped investments hide the real question — does GSFC ever surface them?

  • Cheap on math. $742M market cap minus $535M long-term investments minus $0.2M borrowings leaves $207M of ex-cash enterprise value against $104M of TTM EBITDA — roughly 2× on the operating engine.
  • Trapped on governance. The Government of Gujarat owns 37.84%; the April 2023 GoG circular requires PSUs to consider buybacks; investors raised the question four times on the Q3 FY25 call and not once since.
  • Resolves in 9 days. The Q4 FY26 board meeting on 19 May 2026 lands first under new MD Dr. Rajender Kumar (installed January 2026) and new auditor CNK & Associates — the textbook setup for either a capital-return signal or another procedural deflection.
The investment book equals 72% of market cap. The market is pricing it at zero.
3 · Money picture

Profits look fine on paper. They have not turned into cash for two straight years.

$1.1B
Revenue (TTM) +12% off FY24 trough
6.2%
FY25 ROCE vs Coromandel 22.8%
30%
3yr CFO / Net income structural divergence
−$95M
2yr cumulative FCF vs $137M reported NI

Other income — dividends and treasury yield on the $535M investment book — supplied 75% of FY24 operating profit and 51% in FY25, against a ~10% baseline. Strip it out and core operating margin is 6.7%, not the 9.99% headline. Inventory days moved from 70 (FY23) to 89 (FY25), absorbing working capital. The dividend is being paid out of investments, not out of current operations — and that is the question the Q4 FY26 cash-flow statement has to answer.

4 · What's actually working

The market still prices GSFC as a chemical-spread cycle. The cycle is fertilizer-led now.

  • Q3 FY26 proved the rotation. PAT +32% YoY came from the fertilizer segment ($12.6M EBIT) while the caprolactam–benzene spread fell to $495/MT — well below management's own $725/MT breakeven. The chemical leg lost money; the regulated leg carried the print.
  • AS volumes +29% in a 14%-down DAP market. India's #1 caprolactam plant (82,704 MT FY25) throws off ammonium-sulphate by-product at near-zero variable cost; FY25 AS volumes hit 521,346 MT while peers FACT and RCF saw net income fall 93% and 75% peak-to-trough.
  • Cost savings are commissioned, not promised. Sulphuric Acid V (198 kTPA, commissioned 7 January 2026) saves ~$10.6M/yr; Urea-II revamp (May 2025) adds $5–6M/yr after the DoF energy-norm refix. Both hit full-year run-rate in FY27.
Stock fell 5% on the Q3 FY26 print despite a +32% PAT beat — sold on a metric that no longer drives the business.
5 · Who runs this

No skin in the game, anywhere — and the bench keeps changing.

  • Zero alignment. No director equity, no ESOP, no LTIP, no insider buys ever. The MD draws zero pay from GSFC (he is on IAS deputation); sitting fees are $185 per meeting, and IAS-cadre directors deposit them straight to the state treasury.
  • Three boardroom events in six months. Two MD changes in 14 months (Kamal Dayani out July 2025, Sanjeev Kumar in August 2025, Dr. Rajender Kumar in January 2026); ED Sanjeev Varma resigned 28 April 2026; new Chairman Manoj Kumar Das also chairs peer GNFC concurrently.
  • The smart money is leaving. Foreign institutional ownership halved from 23.79% (March 2022) to 11.83% (March 2025). BSE imposed a ~$10,500 fine in November 2025 for missing independent directors — a live LODR breach GSFC has appealed.
Promoter (Government of Gujarat) sets the agenda; nobody on the board has a single share at risk.
6 · The next 90 days

One hard date carries the year. Two procedural windows follow.

  • 19–20 May 2026 — Q4 FY26 results. First full year reported under new auditor CNK & Associates; first call under the new MD. Look past the PAT headline to (a) the cash-flow statement, (b) inventory days against 89 at FY25, and (c) any reference to the April 2023 GoG buyback circular.
  • Late May 2026 — Monsoon + spread. IMD long-range forecast underwrites the 23–24 lakh MT FY26 fertilizer guidance and the Q1 FY27 ramp. Management said the caprolactam–benzene spread improved to $590/MT in January 2026 from $495/MT in Q3 — the Q4 IP-segment EBIT calibrates whether the chemical leg has stabilised.
  • August 2026 — DGTR ruling window. Management has formally requested anti-dumping duty on caprolactam, melamine, and nylon-6; "still under consideration" as of Q3 FY26. Without a provisional duty before the August quarter-end, US tariffs on China reroute Chinese volumes into India and the moat fails the stress test.
7 · Bull & Bear

Lean cautious — but the fork is dated and observable.

  • For. Operating engine at ~2× EV/EBITDA after netting $535M of investments and $0.2M of debt; commissioned cost savings (Sulphuric Acid V, Urea-II) reach full-year run-rate in FY27; the new MD / new Chairman / new auditor combination with capex completed is the textbook setup for a capital reset.
  • For. The caprolactam–AS captive loop survived the worst trough in a decade — FY24–25 net income fell 53% peak-to-trough at GSFC vs −93% at FACT and −75% at RCF; the HX Crystal monopoly (commissioned October 2024) adds a third independent industrial leg.
  • Against. 6% ROCE for a decade against peers earning 22–26% on the same NBS regime; 30% three-year cash conversion; the 0.56× P/B is rational pricing of a sub-cost-of-capital business, not opportunity.
  • Against. No mechanism to surface $535M of investments — the buyback question went silent after Q3 FY25, two MD changes in 14 months, FII halved from 23.79% to 11.83%. Informed allocators are voting on exactly the question the bull is now asking.
Watchlist, not own. Flips to lean long on a board-sanctioned capital return ≥ $53M or special dividend ≥ $0.16/share. Flips to avoid on a third consecutive negative-FCF year with CFO/NI under 50%.

Watchlist to re-rate: (1) FY26 operating cash flow on 19 May 2026; (2) any explicit commentary from the new MD on the April 2023 GoG buyback circular; (3) DGTR provisional duty notification on caprolactam by the August quarter-end.